

09/541,752

O.K. to enter
Jed 11.22.03

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of reducing cell proliferation or extracellular matrix production caused by zveg3 in a mammal comprising administering to the mammal a composition comprising a zveg3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, in an amount sufficient to reduce ~~cell proliferation or extracellular matrix production~~ zveg3 activity, wherein said zveg3 antagonist is an antibody that specifically binds to a dimeric protein having two polypeptide chains, wherein each of said polypeptide chains consists of a sequence of amino acid residues selected from the group consisting of:

residues 230-345 of SEQ ID NO:2;
residues 231-345 of SEQ ID NO:2;
residues 232-345 of SEQ ID NO:2;
residues 233-345 of SEQ ID NO:2;
residues 234-345 of SEQ ID NO:2;
residues 235-345 of SEQ ID NO:2;
residues 236-345 of SEQ ID NO:2;
residues 237-345 of SEQ ID NO:2;
residues 238-345 of SEQ ID NO:2;
residues 239-345 of SEQ ID NO:2; and
residues 240-345 of SEQ ID NO:2;

whereby administration of the composition to the mammal results in reduction of cell proliferation or extracellular matrix production caused by zveg3.

2. (original) The method of claim 1 wherein proliferation of mesangial, endothelial, smooth muscle, fibroblast, osteoblast, osteoclast, stellate, or interstitial cells is reduced.

3. (original) The method of claim 1 wherein extracellular matrix production is reduced.

4. (original) The method of claim 1 wherein the mammal is suffering from a fibroproliferative disorder of the liver.